Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch‐repair deficiency
- 16 February 2024
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 263 (1) , 32-46
Abstract
Cholangiolocarcinoma (CLC) is a primary liver carcinoma that resembles the canals of Hering and that has been reported to be associated with stem cell features. Due to its rarity, the nature of CLC remains unclear, and its pathological classification remains controversial. To clarify the positioning of CLC in primary liver cancers and identify characteristics that could distinguish CLC from other liver cancers, we performed integrated analyses using whole‐exome sequencing (WES), immunohistochemistry, and a retrospective review of clinical information on eight CLC cases and two cases of recurrent CLC. WES demonstrated that CLC includes IDH1 and BAP1 mutations, which are characteristic of intrahepatic cholangiocarcinoma (iCCA). A mutational signature analysis showed a pattern similar to that of iCCA, which was different from that of hepatocellular carcinoma (HCC). CLC cells, including CK7, CK19, and EpCAM, were positive for cholangiocytic differentiation markers. However, the hepatocytic differentiation marker AFP and stem cell marker SALL4 were completely negative. The immunostaining patterns of CLC with CD56 and epithelial membrane antigen were similar to those of the noncancerous bile ductules. In contrast, mutational signature cluster analyses revealed that CLC formed a cluster associated with mismatch‐repair deficiency (dMMR), which was separate from iCCA. Therefore, to evaluate MMR status, we performed immunostaining of four MMR proteins (PMS2, MSH6, MLH1, and MSH2) and detected dMMR in almost all CLCs. In conclusion, CLC had highly similar characteristics to iCCA but not to HCC. CLC can be categorized as a subtype of iCCA. In contrast, CLC has characteristics of dMMR tumors that are not found in iCCA, suggesting that it should be treated distinctly from iCCA. © 2024 The Pathological Society of Great Britain and Ireland.Keywords
Funding Information
- Japan Society for the Promotion of Science (19K07459, 19K09145, 22K04845, 23K06362)
This publication has 66 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing dataNucleic Acids Research, 2013
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and explorationBriefings in Bioinformatics, 2012
- Morphometric and immunohistochemical study of cholangiolocellular carcinoma: comparison with non‐neoplastic cholangiole, interlobular duct and septal ductJournal of Hepato-Biliary-Pancreatic Sciences, 2011
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancersGenome Biology, 2011
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell originHepatology, 2008
- Patterns of somatic mutation in human cancer genomesNature, 2007
- GenePattern 2.0Nature Genetics, 2006
- Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomasJournal of Hepatology, 2004